[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Secures US$80 Million Deal For GLP-1/GIP Drug Rights",
    "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094. Concurrently, interim results from their Phase 2 COURAGE trial revealed continuing investigations of semaglutide and trevogrumab combinations, emphasizing regulatory and market complexities. Despite these developments, Regeneron’s share price fell by 17% over the past week, contrasting sharply with a 2%...",
    "url": "https://finnhub.io/api/news?id=d681c47f27e726f7f1c53ec8be11b28ab662b822879c62cbeee2370bd1cbb9d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748971462,
      "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Secures US$80 Million Deal For GLP-1/GIP Drug Rights",
      "id": 134982448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094. Concurrently, interim results from their Phase 2 COURAGE trial revealed continuing investigations of semaglutide and trevogrumab combinations, emphasizing regulatory and market complexities. Despite these developments, Regeneron’s share price fell by 17% over the past week, contrasting sharply with a 2%...",
      "url": "https://finnhub.io/api/news?id=d681c47f27e726f7f1c53ec8be11b28ab662b822879c62cbeee2370bd1cbb9d8"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron price target lowered to $600 from $800 at BMO Capital",
    "summary": "BMO Capital lowered the firm’s price target on Regeneron (REGN) to $600 from $800 and keeps an Outperform rating on the shares. The firm is updating its model following “disappointing” results for itepekimab in COPD, noting that with only one of the two phase 3 studies reaching statistical significance and the path forward for approval more difficult, it is lowering its probability of success for itepekimab to 0%, the analyst tells investors in a research note. Published first on TheFly – the ul",
    "url": "https://finnhub.io/api/news?id=6bda4ec2b1a50bbd8889a728fc5844a71119d012d9057a75e831431d72b62c48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748955932,
      "headline": "Regeneron price target lowered to $600 from $800 at BMO Capital",
      "id": 134979254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "BMO Capital lowered the firm’s price target on Regeneron (REGN) to $600 from $800 and keeps an Outperform rating on the shares. The firm is updating its model following “disappointing” results for itepekimab in COPD, noting that with only one of the two phase 3 studies reaching statistical significance and the path forward for approval more difficult, it is lowering its probability of success for itepekimab to 0%, the analyst tells investors in a research note. Published first on TheFly – the ul",
      "url": "https://finnhub.io/api/news?id=6bda4ec2b1a50bbd8889a728fc5844a71119d012d9057a75e831431d72b62c48"
    }
  },
  {
    "ts": null,
    "headline": "What Investors Should Look Out For In May 2025's Job Report",
    "summary": "Investors may likely dismiss the upcoming May jobs report this Friday, despite potential job losses in government sector. Check out the latest market outlook.",
    "url": "https://finnhub.io/api/news?id=9b841be06cbf768c94aa16322d6470783b9d33955d851389453451f12591eb09",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748952321,
      "headline": "What Investors Should Look Out For In May 2025's Job Report",
      "id": 134979195,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1393736657/image_1393736657.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Investors may likely dismiss the upcoming May jobs report this Friday, despite potential job losses in government sector. Check out the latest market outlook.",
      "url": "https://finnhub.io/api/news?id=9b841be06cbf768c94aa16322d6470783b9d33955d851389453451f12591eb09"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron to acquire rights for Hansoh’s HS-20094 therapy",
    "summary": "Regeneron will pay Hansoh $80m upfront, with additional milestone payments that could reach $1.93bn.",
    "url": "https://finnhub.io/api/news?id=c59f3a1776e0ac4a7f6a80402e2bdb4e428e5184d837c3dc00d43194daf7f98d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748940723,
      "headline": "Regeneron to acquire rights for Hansoh’s HS-20094 therapy",
      "id": 134979255,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron will pay Hansoh $80m upfront, with additional milestone payments that could reach $1.93bn.",
      "url": "https://finnhub.io/api/news?id=c59f3a1776e0ac4a7f6a80402e2bdb4e428e5184d837c3dc00d43194daf7f98d"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Jumps 6.2% In May To Log Best Month Since 2023",
    "summary": "US stocks broadly jumped in May, with the S&P 500 registering its best month in over a year.",
    "url": "https://finnhub.io/api/news?id=a87240eac9e4b5631212549d6a8180fb3c398d5bc6b3143c67d4a7e62c2fce33",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748929140,
      "headline": "S&P 500 Jumps 6.2% In May To Log Best Month Since 2023",
      "id": 134975020,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1259980515/image_1259980515.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "US stocks broadly jumped in May, with the S&P 500 registering its best month in over a year.",
      "url": "https://finnhub.io/api/news?id=a87240eac9e4b5631212549d6a8180fb3c398d5bc6b3143c67d4a7e62c2fce33"
    }
  }
]